Answers are grounded in this paper and cite their sources.
Despite recent therapeutic advances including SGLT2 inhibitors, vericiguat, and transcatheter mitral valve repair, HFrEF continues to have high morbidity and mortality.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: